Pular para o conteúdo principal
Ranking Invest

GPCR - Structure Therapeutics Inc.

Segmento: HealthcareStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valor de Mercado
$ 1.56 Bi
IVR
0.55Índice proprietário de comparação relativa: 0,55.
IVR2
-0.34Leitura proprietária complementar: -34%.
MLL
-0.34Leitura proprietária complementar: -34%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 1.35 Bi

Dívida Líquida

-$ 272.64 Mi

L4T

-$ 214.84 Mi

Indicadores Básicos

ROE

-15.86%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

C0.32

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

F-6.51

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.20

DIV/L4T

1.27

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.